Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. registers 1,115,500 common shares issuable upon the exercise of warrants under a prospectus supplement amending the April 10, 2025 prospectus.
The supplement attaches the Form 10-K for the fiscal year ended December 31, 2025 and updates related disclosures. The Public Warrants have an exercise price of $4.64 and an expiration date of November 15, 2029. The common shares and Public Warrants trade on Nasdaq under the symbols MDCX and MDCXW. Shares outstanding were 39,362,109 common shares as of March 17, 2026.
Medicus Pharma Ltd. registers up to 7,500,000 common shares via a prospectus supplement to its effective Registration Statement on Form S-1.
The supplement incorporates the Company’s Form 10-K filed March 25, 2026, and notes 39,362,109 common shares outstanding as of March 17, 2026. The Company’s common shares trade on Nasdaq under the symbol MDCX; the last reported sales price on March 24, 2026 was $0.49.
Medicus Pharma Ltd. is a clinical-stage biotech company developing two main assets: SkinJect’s doxorubicin-containing microneedle array (D‑MNA) for non‑melanoma skin cancers and Antev’s Teverelix, a long‑acting GnRH antagonist for advanced prostate cancer and acute urinary retention.
The company completed a reverse takeover of SkinJect in 2023, listed on Nasdaq in 2024, and voluntarily delisted from the TSX Venture Exchange in 2025. As of March 17, 2026, it had 39,362,109 common shares outstanding and a non‑affiliate market value of about $28.3 million as of June 30, 2025.
SkinJect’s Phase 1 trial met safety and secondary efficacy endpoints, and a 90‑patient Phase 2 study (SKNJCT‑003) in nodular BCC has completed enrollment, with topline data showing the 200 µg dose achieving 73% clinical and 40% histological clearance at Day 57. A UAE Phase 2 trial (SKNJCT‑004) is also underway.
In August 2025, Medicus acquired 98.6% of Antev for roughly $2.97 million in cash plus 1,603,164 shares, with up to $65 million in contingent FDA milestone payments. Teverelix holds composition and process patents out to 2039 and beyond, with FDA‑cleared Phase 2b programs in both advanced prostate cancer and acute urinary retention.
Medicus maintains extensive microneedle IP licensed from the University of Pittsburgh, global Teverelix patents, and several non‑binding collaborations, including with HelixNano on mRNA‑based vaccines and Reliant AI on AI‑driven clinical development. The company has 16 full‑time employees and qualifies as an emerging growth and smaller reporting company, allowing scaled U.S. disclosure requirements.
Medicus Pharma Ltd. registers 1,115,500 common shares issuable upon the exercise of warrants, as set forth in Prospectus Supplement No. 22 dated March 6, 2026. The supplement attaches a Current Report on Form 8-K and updates the April 10, 2025 prospectus.
The supplement restates the Public Warrants' exercise price $4.64 and expiration date November 15, 2029, and notes last reported Nasdaq prices on March 5, 2026 of $0.68 (common share) and $1.00 (Public Warrant). The Form 8-K discloses prior unregistered sales under a SEPA to YA II PN, Ltd. totaling 4,471,038 common shares for aggregate consideration of $3,846,910, and that part of those proceeds prepaid a Yorkville debenture.
Medicus Pharma Ltd. files a prospectus supplement registering up to 1,397,184 common shares and amends the Prospectus dated November 14, 2025 to incorporate its Form 8-K dated March 6, 2026. The supplement notes the company completed multiple unregistered sales to Yorkville under a Standby Equity Purchase Agreement, totaling $3,846,910 for 4,471,038 common shares as detailed in the attached table.
Medicus Pharma Ltd. registers 2,260,000 common shares issuable upon the exercise of public warrants under a prospectus supplement dated March 6, 2026. This supplement amends the May 29, 2025 prospectus and incorporates a Form 8-K filed March 6, 2026.
The Form 8-K discloses prior sales under a Standby Equity Purchase Agreement totaling 4,471,038 common shares for aggregate consideration of $3,846,910 (sales dated December 19, 2025 through March 6, 2026). The supplement notes the public warrants have an exercise price of $4.64 and expire on November 15, 2029; market prices quoted were $0.68 per common share and $1.00 per Public Warrant as of March 5, 2026.
Medicus Pharma Ltd. files a prospectus supplement registering up to 7,500,000 common shares and attaches a Form 8-K reporting equity financings under a Standby Equity Purchase Agreement.
The Form 8-K lists completed SEPA sales totaling 4,471,038 common shares for aggregate consideration of $3,846,910, and states Yorkville may purchase additional shares "subject to the satisfaction or waiver of the conditions and limitations set forth in the SEPA". The company notes its Nasdaq last sale price was $0.68.
Medicus Pharma Ltd. reported that it sold a total of 4,471,038 common shares to YA II PN, Ltd. (Yorkville) under a previously disclosed Standby Equity Purchase Agreement. These unregistered sales, completed between December 19, 2025 and March 6, 2026, generated approximate aggregate consideration of $3,846,910.
The company has used part of the net proceeds to prepay a portion of an outstanding debenture held by Yorkville, reducing that obligation. The shares were issued in private transactions relying on the Section 4(a)(2) exemption from registration, and Yorkville may resell them under an effective registration statement while Medicus may request additional share purchases under the SEPA, subject to its conditions and limitations.
Medicus Pharma Ltd. has filed a resale registration covering up to 4,020,000 common shares issuable on exercise of existing Private Warrants held by Armistice Capital Master Fund Ltd. Each warrant is immediately exercisable for one common share at an exercise price of $2.00 and expires on June 5, 2031.
The company is not selling shares in this registration and will not receive proceeds from resales by the selling shareholder, though it may receive up to $8,040,000 if the warrants are exercised for cash. Common shares trade on Nasdaq under “MDCX,” and the company qualifies as an emerging growth and smaller reporting company.